SlideShare a Scribd company logo
Transgenic CETP Dahl Salt-sensitive
(Tg53) Rat Model
“Is it promising enough?”
Victoria L. M. Herrera, M.D.
Associate Professor of Medicine
Section of Molecular Genetics
Whitaker Cardiovascular Institute
Boston University School of Medicine
700 Albany Street – W609, Boston MA 02118
vherrera@bu.edu
Tg53 rat model – “is it promising enough?”
Question analyzed –
• a provocative but necessary question posed by
Symposium organizers
• modeling the “vulnerable plaque” has been an
underestimated challenge
• a review of multi-species animal models of
atherosclerosis from the 1960s underscores this
challenge
Modeling vulnerable plaque – an underestimated challenge
Analysis of coronary artery
disease at end-stage
plq
hge
plq
eros’n
plq
fissure
plq
thombosis occlus’n
Pigeon: Carneau, Show Racer
* aortic root
nr + nr nr +
Monkey: a. Cynomolgus
b. African green
c. Rhesus
+
+
nr
nr
nr
nr
nr
nr
nr
nr
nr
nr
+
+
Pig: a. thiouracil + xrad’n
b. FHC: hyperLDL-emia
+
+
nr
nr
+
nr
some
some
+
+
Rabbit: WatanabeHHL
* coronary ostia
nr nr nr nr +
Mouse: ApoE/LDLr knockout nr nr nr nr +
Rat: Tg53 rat model + + + + +
[nr, not reported; +, present]
Elements of a “promising model”
Simulation of coronary artery disease
– plaque site
– disease course
– plaque progression
Model advantages as experimental system
– reproducibility
– duration to valid endpoints
– defined genetic background
– accessible phenotype manipulation
Model value and potential
– as investigative instrument
– as pre-clinical platform
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque site
 plaque predilection site = coronary arteries
 in contrast to: aortic root plaque predilection site in
mouse models described to date
Tg53 end-stage
plaques in proximal
right coronary artery
[PTAH stain, 40x
original mag]
RV
Ao
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
disease course
 risk factors consistent with human CHD
• hypertension exacerbates phenotype
• atherogenic lipid profile: increased total
cholesterol and triglyceride levels, low HDL,
increased VLDLc and VLDLtg, increased small
LDLc
• hyperlipidemia increases with age
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
disease course
 decreased survival compared with non-transgenic –
non-hyperlipidemic, hypertensive, Dahl S rat
controls on regular rat chow [Nat Med 5: 383, 1999; Mol
Med 7:831, 2001].
 “end-stage” simulates cardiac endpoints of CHD
• (+) cardio-respiratory distress
• (+) signs of heart failure
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque progression
 “culprit” plaque features: foam-cell rich, paucity of smcs, leukocyte
adhesion, intraplaque thrombi, erosion, plaque shoulder
susceptibility
Masson – trichrome stain 400x orig mag PTAH; 1000x orig
mag
Elements of a “promising model”
Masson – trichrome; 1000x orig
mag
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque progression
 “culprit plaque features: foam-cell rich, intraplaque hemorrhage,
paucity of smcs, lipid core > 1/3 of plaque volume
smc α-actin, Fast red im-stn; 400x
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque progression
 “culprit” plaque features: fibrin-positive thrombosis in
proximal coronary lesions; none detected in more distal
stable lesions
PTAH: fibrin(+) thrombus; prox lesion PTAH: distal stable lesion
Elements of a “promising model”
Tg53 rat model simulates human coronary heart
disease (CHD)
plaque progression
 recapitulates lesion heterogeneity of “culprit” plaques
associated with human acute coronary syndromes
PTAH: thick cap, smc-rich, but with
intraplq hge & thrombosis, IEL disrup’n
PTAH: reduced cap & smc; foam-cell
rich; + intraplq hge & thrombosis,
Elements of a “promising model”
Tg53 rat model: advantages as experimental system
 reproducibility and robustness of phenotype
• lipid profile: increased total cholesterol and
triglycerides predominantly in VLDL, low HDL
• “culprit” plaque phenotype in proximal right coronary
artery
• “stable” occlusive plaque in smaller coronary arteries
 reasonable duration to valid endpoints
• 6-9+ month range of proximal coronary plaque
development on regular rat chow: eccentric
macrophage-foam cell rich plaque which progresses to
“culprit” plaque at endstage
Elements of a “promising model”
Tg53 rat model: advantages as experimental system
 defined genetic background – eliminates
differential genetic susceptibility as confounder
• inbred Dahl salt-sensitive hypertensive rat strain
 accessible phenotype manipulation – onset and
course of hyperlipidemia and coronary artery
disease can be experimentally manipulated
• Western Type Diet (0.15% cholesterol) accelerates
onset and levels of hyperlipidemia
• low salt diet (0.0038% NaCl), which reduces level of
hypertension, attenuates coronary artery disease hence
increasing survival
Elements of a “promising model”
 Tg53 rat model: value and potential
 identical genetic background and ability to
regulate environmental factors allows well-
controlled in vivo studies for cross-talk
pathogenesis:
a. investigation of mechanisms of coronary
plaque development not possible in humans
b. methodical in vivo investigation of novel
intervention targets
c. maximization of genomic-based technologies
aimed at the investigation of mechanisms and
targets
Elements of a “promising model”
 Tg53 rat model: value and potential
 coronary-specific experimental design for
coronary artery-disease studies: with cumulative
evidence of vessel-specific genetic factors, the
Tg53 coronary-specific phenotype is key
 combinatorial modeling: well characterized
inbred rat strains allow cross-breeding for
interaction studies relevant to human disease
 hypertension
• diabetes
• obesity
Elements of a “promising model”
 Tg53 rat model: value and potential
 as investigative tool: invaluable new insight
distinct from that observed in current other models
– as a beginning,
1. prelude to culprit plaque: the eccentric macrophage
foam-cell rich lesion becomes the “culprit” plaque, thus
experimentally “capturing” the beginning of the
vulnerable plaque
2. differential pathway hypothesis: proximal vulnerable-
culprit coronary lesions develop distinct from more
distal stable coronary plaques
3. lesion heterogeneity paradigm: given identical genetic
background and environmental factors, lesion
heterogeneity at end-stage reflect stochastic endpoints
of a common pathogenic framework
Elements of a “promising model”
 Tg53 rat model: value and potential
 as pre-clinical platform
• identical genetic background
• regulated environmental factors
• robust coronary phenotype
• instrumentation accessibility
• rat physiological and pharmacological information
database
– allow continuity of comparative analysis for
successful new intervention and prevention
strategies
• ... can’t promise the world – but along with
other animal models, can together make a
better promise,
• but then again, which model can be
“promising enough” since even humans –
although they are the ultimate benchmarks –
make terrible models, if not the worst, for
human coronary artery disease ...

Tg53 rat model – “is it promising enough?”
Acknowledgment
• This work is supported by grants from the
National Institutes of Health and American
Heart Association.

More Related Content

Viewers also liked

067 the holy grail of cardiology
067 the holy grail of cardiology067 the holy grail of cardiology
067 the holy grail of cardiology
SHAPE Society
 
167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological media167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological media
SHAPE Society
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
SHAPE Society
 
104 new advances in thermography
104 new advances in thermography104 new advances in thermography
104 new advances in thermography
SHAPE Society
 
033 uptakes of spio by murine
033 uptakes of spio by murine033 uptakes of spio by murine
033 uptakes of spio by murine
SHAPE Society
 
501 autoimmune disease
501 autoimmune disease501 autoimmune disease
501 autoimmune disease
SHAPE Society
 
1688 azadpour 3 12 02
1688 azadpour 3 12 021688 azadpour 3 12 02
1688 azadpour 3 12 02
SHAPE Society
 
178 vaccination against atherosclerosis
178 vaccination against atherosclerosis178 vaccination against atherosclerosis
178 vaccination against atherosclerosis
SHAPE Society
 
082 smoking and plaque inflammation
082 smoking and plaque inflammation082 smoking and plaque inflammation
082 smoking and plaque inflammation
SHAPE Society
 
160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium
SHAPE Society
 
130 mri assessment of human atherosclerotic disease
130 mri assessment of human atherosclerotic disease130 mri assessment of human atherosclerotic disease
130 mri assessment of human atherosclerotic disease
SHAPE Society
 
227 which serum should be used
227 which serum should be used227 which serum should be used
227 which serum should be used
SHAPE Society
 
142 arterial remodelling in coronary syndromes
142 arterial remodelling in coronary syndromes142 arterial remodelling in coronary syndromes
142 arterial remodelling in coronary syndromes
SHAPE Society
 
031
031031
094 spectroscopic fiber optic catheter
094 spectroscopic fiber optic catheter094 spectroscopic fiber optic catheter
094 spectroscopic fiber optic catheter
SHAPE Society
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
SHAPE Society
 
133 testosterone and neo intimal plaque development
133 testosterone and neo intimal plaque development133 testosterone and neo intimal plaque development
133 testosterone and neo intimal plaque development
SHAPE Society
 
055 mri applications in cardiovascular medicine
055 mri applications in cardiovascular medicine055 mri applications in cardiovascular medicine
055 mri applications in cardiovascular medicine
SHAPE Society
 
116 stabilization of vulnerable plaques
116 stabilization of vulnerable plaques116 stabilization of vulnerable plaques
116 stabilization of vulnerable plaques
SHAPE Society
 
172 nir spectroscopy
172 nir spectroscopy172 nir spectroscopy
172 nir spectroscopy
SHAPE Society
 

Viewers also liked (20)

067 the holy grail of cardiology
067 the holy grail of cardiology067 the holy grail of cardiology
067 the holy grail of cardiology
 
167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological media167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological media
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
104 new advances in thermography
104 new advances in thermography104 new advances in thermography
104 new advances in thermography
 
033 uptakes of spio by murine
033 uptakes of spio by murine033 uptakes of spio by murine
033 uptakes of spio by murine
 
501 autoimmune disease
501 autoimmune disease501 autoimmune disease
501 autoimmune disease
 
1688 azadpour 3 12 02
1688 azadpour 3 12 021688 azadpour 3 12 02
1688 azadpour 3 12 02
 
178 vaccination against atherosclerosis
178 vaccination against atherosclerosis178 vaccination against atherosclerosis
178 vaccination against atherosclerosis
 
082 smoking and plaque inflammation
082 smoking and plaque inflammation082 smoking and plaque inflammation
082 smoking and plaque inflammation
 
160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium
 
130 mri assessment of human atherosclerotic disease
130 mri assessment of human atherosclerotic disease130 mri assessment of human atherosclerotic disease
130 mri assessment of human atherosclerotic disease
 
227 which serum should be used
227 which serum should be used227 which serum should be used
227 which serum should be used
 
142 arterial remodelling in coronary syndromes
142 arterial remodelling in coronary syndromes142 arterial remodelling in coronary syndromes
142 arterial remodelling in coronary syndromes
 
031
031031
031
 
094 spectroscopic fiber optic catheter
094 spectroscopic fiber optic catheter094 spectroscopic fiber optic catheter
094 spectroscopic fiber optic catheter
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
 
133 testosterone and neo intimal plaque development
133 testosterone and neo intimal plaque development133 testosterone and neo intimal plaque development
133 testosterone and neo intimal plaque development
 
055 mri applications in cardiovascular medicine
055 mri applications in cardiovascular medicine055 mri applications in cardiovascular medicine
055 mri applications in cardiovascular medicine
 
116 stabilization of vulnerable plaques
116 stabilization of vulnerable plaques116 stabilization of vulnerable plaques
116 stabilization of vulnerable plaques
 
172 nir spectroscopy
172 nir spectroscopy172 nir spectroscopy
172 nir spectroscopy
 

Similar to 3rd vp symposium herrera

SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH Vets
 
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
Mohsin Maqbool
 
Telomeres, Telomerase, and TA-65
Telomeres, Telomerase, and TA-65Telomeres, Telomerase, and TA-65
Telomeres, Telomerase, and TA-65
telomerescience
 
Hodgkins lymphoma kiran
Hodgkins lymphoma   kiranHodgkins lymphoma   kiran
Hodgkins lymphoma kiran
Kiran Ramakrishna
 
V_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_GujralV_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_Gujral
EAFO1
 
Dr. Randall Prather - PRRS Resistant Pigs
Dr. Randall Prather - PRRS Resistant PigsDr. Randall Prather - PRRS Resistant Pigs
Dr. Randall Prather - PRRS Resistant Pigs
John Blue
 
Donor Selection: Unrealted donor transplant. Prof. Richard Champlin
Donor Selection: Unrealted donor transplant. Prof. Richard ChamplinDonor Selection: Unrealted donor transplant. Prof. Richard Champlin
Donor Selection: Unrealted donor transplant. Prof. Richard Champlin
spa718
 
Kennedy takotsubo qrw aug 2015
Kennedy takotsubo qrw aug 2015Kennedy takotsubo qrw aug 2015
Kennedy takotsubo qrw aug 2015
Martin Kennedy
 
Paediatric Cushing’s disease.pptx
Paediatric Cushing’s disease.pptxPaediatric Cushing’s disease.pptx
Paediatric Cushing’s disease.pptx
Dr Pushpender Khatana
 
Percutaneous coronary intervention by hossein
Percutaneous coronary intervention  by hosseinPercutaneous coronary intervention  by hossein
Percutaneous coronary intervention by hossein
Society for Heart Attack Prevention and Eradication
 
032 hossein eftekhari,md
032 hossein eftekhari,md032 hossein eftekhari,md
032 hossein eftekhari,md
032 hossein eftekhari,md032 hossein eftekhari,md
032 hossein eftekhari,md
SHAPE Society
 
2014 07 ismb personalized medicine
2014 07 ismb personalized medicine2014 07 ismb personalized medicine
2014 07 ismb personalized medicine
University of California, San Francisco
 
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Andrew Su
 
Big data exposome and pediatric outcomes
Big data exposome and pediatric outcomesBig data exposome and pediatric outcomes
Big data exposome and pediatric outcomes
Chirag Patel
 
J Immunol-2010-Yin-5828-34
J Immunol-2010-Yin-5828-34J Immunol-2010-Yin-5828-34
J Immunol-2010-Yin-5828-34
Chun-Yu Yen
 
Stem cell therapy : A hope to "No Hope Disorders" Diseased Dr. Sharda Jain
Stem cell therapy : A hope to "No Hope Disorders"  Diseased Dr. Sharda Jain Stem cell therapy : A hope to "No Hope Disorders"  Diseased Dr. Sharda Jain
Stem cell therapy : A hope to "No Hope Disorders" Diseased Dr. Sharda Jain
Lifecare Centre
 
Mast cell disorders
Mast cell disordersMast cell disorders
Presentation: TGA considerations for preclinical studies of cell therapy prod...
Presentation: TGA considerations for preclinical studies of cell therapy prod...Presentation: TGA considerations for preclinical studies of cell therapy prod...
Presentation: TGA considerations for preclinical studies of cell therapy prod...
TGA Australia
 
LEUKEMIA.pptx
LEUKEMIA.pptxLEUKEMIA.pptx
LEUKEMIA.pptx
Kiran Ramakrishna
 

Similar to 3rd vp symposium herrera (20)

SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
SASH : Nailing the diagnosis pathology by Dr Sophia Tzannes
 
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
 
Telomeres, Telomerase, and TA-65
Telomeres, Telomerase, and TA-65Telomeres, Telomerase, and TA-65
Telomeres, Telomerase, and TA-65
 
Hodgkins lymphoma kiran
Hodgkins lymphoma   kiranHodgkins lymphoma   kiran
Hodgkins lymphoma kiran
 
V_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_GujralV_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_Gujral
 
Dr. Randall Prather - PRRS Resistant Pigs
Dr. Randall Prather - PRRS Resistant PigsDr. Randall Prather - PRRS Resistant Pigs
Dr. Randall Prather - PRRS Resistant Pigs
 
Donor Selection: Unrealted donor transplant. Prof. Richard Champlin
Donor Selection: Unrealted donor transplant. Prof. Richard ChamplinDonor Selection: Unrealted donor transplant. Prof. Richard Champlin
Donor Selection: Unrealted donor transplant. Prof. Richard Champlin
 
Kennedy takotsubo qrw aug 2015
Kennedy takotsubo qrw aug 2015Kennedy takotsubo qrw aug 2015
Kennedy takotsubo qrw aug 2015
 
Paediatric Cushing’s disease.pptx
Paediatric Cushing’s disease.pptxPaediatric Cushing’s disease.pptx
Paediatric Cushing’s disease.pptx
 
Percutaneous coronary intervention by hossein
Percutaneous coronary intervention  by hosseinPercutaneous coronary intervention  by hossein
Percutaneous coronary intervention by hossein
 
032 hossein eftekhari,md
032 hossein eftekhari,md032 hossein eftekhari,md
032 hossein eftekhari,md
 
032 hossein eftekhari,md
032 hossein eftekhari,md032 hossein eftekhari,md
032 hossein eftekhari,md
 
2014 07 ismb personalized medicine
2014 07 ismb personalized medicine2014 07 ismb personalized medicine
2014 07 ismb personalized medicine
 
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
Microtask crowdsourcing for annotating diseases in PubMed abstracts (ASHG 2014)
 
Big data exposome and pediatric outcomes
Big data exposome and pediatric outcomesBig data exposome and pediatric outcomes
Big data exposome and pediatric outcomes
 
J Immunol-2010-Yin-5828-34
J Immunol-2010-Yin-5828-34J Immunol-2010-Yin-5828-34
J Immunol-2010-Yin-5828-34
 
Stem cell therapy : A hope to "No Hope Disorders" Diseased Dr. Sharda Jain
Stem cell therapy : A hope to "No Hope Disorders"  Diseased Dr. Sharda Jain Stem cell therapy : A hope to "No Hope Disorders"  Diseased Dr. Sharda Jain
Stem cell therapy : A hope to "No Hope Disorders" Diseased Dr. Sharda Jain
 
Mast cell disorders
Mast cell disordersMast cell disorders
Mast cell disorders
 
Presentation: TGA considerations for preclinical studies of cell therapy prod...
Presentation: TGA considerations for preclinical studies of cell therapy prod...Presentation: TGA considerations for preclinical studies of cell therapy prod...
Presentation: TGA considerations for preclinical studies of cell therapy prod...
 
LEUKEMIA.pptx
LEUKEMIA.pptxLEUKEMIA.pptx
LEUKEMIA.pptx
 

More from SHAPE Society

Barth imt
Barth imtBarth imt
Barth imt
SHAPE Society
 
Braunwald
BraunwaldBraunwald
Braunwald
SHAPE Society
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
SHAPE Society
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
SHAPE Society
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
SHAPE Society
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
SHAPE Society
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
SHAPE Society
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
SHAPE Society
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
SHAPE Society
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
SHAPE Society
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
SHAPE Society
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
SHAPE Society
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
SHAPE Society
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
SHAPE Society
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
SHAPE Society
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
SHAPE Society
 
A20 gene
A20 geneA20 gene
A20 gene
SHAPE Society
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
SHAPE Society
 
103100
103100103100
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
SHAPE Society
 

More from SHAPE Society (20)

Barth imt
Barth imtBarth imt
Barth imt
 
Braunwald
BraunwaldBraunwald
Braunwald
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
 
A20 gene
A20 geneA20 gene
A20 gene
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
 
103100
103100103100
103100
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 

Recently uploaded

Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
KafrELShiekh University
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 

Recently uploaded (20)

Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 

3rd vp symposium herrera

  • 1. Transgenic CETP Dahl Salt-sensitive (Tg53) Rat Model “Is it promising enough?”
  • 2. Victoria L. M. Herrera, M.D. Associate Professor of Medicine Section of Molecular Genetics Whitaker Cardiovascular Institute Boston University School of Medicine 700 Albany Street – W609, Boston MA 02118 vherrera@bu.edu
  • 3. Tg53 rat model – “is it promising enough?” Question analyzed – • a provocative but necessary question posed by Symposium organizers • modeling the “vulnerable plaque” has been an underestimated challenge • a review of multi-species animal models of atherosclerosis from the 1960s underscores this challenge
  • 4. Modeling vulnerable plaque – an underestimated challenge Analysis of coronary artery disease at end-stage plq hge plq eros’n plq fissure plq thombosis occlus’n Pigeon: Carneau, Show Racer * aortic root nr + nr nr + Monkey: a. Cynomolgus b. African green c. Rhesus + + nr nr nr nr nr nr nr nr nr nr + + Pig: a. thiouracil + xrad’n b. FHC: hyperLDL-emia + + nr nr + nr some some + + Rabbit: WatanabeHHL * coronary ostia nr nr nr nr + Mouse: ApoE/LDLr knockout nr nr nr nr + Rat: Tg53 rat model + + + + + [nr, not reported; +, present]
  • 5. Elements of a “promising model” Simulation of coronary artery disease – plaque site – disease course – plaque progression Model advantages as experimental system – reproducibility – duration to valid endpoints – defined genetic background – accessible phenotype manipulation Model value and potential – as investigative instrument – as pre-clinical platform
  • 6. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) plaque site  plaque predilection site = coronary arteries  in contrast to: aortic root plaque predilection site in mouse models described to date Tg53 end-stage plaques in proximal right coronary artery [PTAH stain, 40x original mag] RV Ao
  • 7. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) disease course  risk factors consistent with human CHD • hypertension exacerbates phenotype • atherogenic lipid profile: increased total cholesterol and triglyceride levels, low HDL, increased VLDLc and VLDLtg, increased small LDLc • hyperlipidemia increases with age
  • 8. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) disease course  decreased survival compared with non-transgenic – non-hyperlipidemic, hypertensive, Dahl S rat controls on regular rat chow [Nat Med 5: 383, 1999; Mol Med 7:831, 2001].  “end-stage” simulates cardiac endpoints of CHD • (+) cardio-respiratory distress • (+) signs of heart failure
  • 9. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) plaque progression  “culprit” plaque features: foam-cell rich, paucity of smcs, leukocyte adhesion, intraplaque thrombi, erosion, plaque shoulder susceptibility Masson – trichrome stain 400x orig mag PTAH; 1000x orig mag
  • 10. Elements of a “promising model” Masson – trichrome; 1000x orig mag Tg53 rat model simulates human coronary heart disease (CHD) plaque progression  “culprit plaque features: foam-cell rich, intraplaque hemorrhage, paucity of smcs, lipid core > 1/3 of plaque volume smc α-actin, Fast red im-stn; 400x
  • 11. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) plaque progression  “culprit” plaque features: fibrin-positive thrombosis in proximal coronary lesions; none detected in more distal stable lesions PTAH: fibrin(+) thrombus; prox lesion PTAH: distal stable lesion
  • 12. Elements of a “promising model” Tg53 rat model simulates human coronary heart disease (CHD) plaque progression  recapitulates lesion heterogeneity of “culprit” plaques associated with human acute coronary syndromes PTAH: thick cap, smc-rich, but with intraplq hge & thrombosis, IEL disrup’n PTAH: reduced cap & smc; foam-cell rich; + intraplq hge & thrombosis,
  • 13. Elements of a “promising model” Tg53 rat model: advantages as experimental system  reproducibility and robustness of phenotype • lipid profile: increased total cholesterol and triglycerides predominantly in VLDL, low HDL • “culprit” plaque phenotype in proximal right coronary artery • “stable” occlusive plaque in smaller coronary arteries  reasonable duration to valid endpoints • 6-9+ month range of proximal coronary plaque development on regular rat chow: eccentric macrophage-foam cell rich plaque which progresses to “culprit” plaque at endstage
  • 14. Elements of a “promising model” Tg53 rat model: advantages as experimental system  defined genetic background – eliminates differential genetic susceptibility as confounder • inbred Dahl salt-sensitive hypertensive rat strain  accessible phenotype manipulation – onset and course of hyperlipidemia and coronary artery disease can be experimentally manipulated • Western Type Diet (0.15% cholesterol) accelerates onset and levels of hyperlipidemia • low salt diet (0.0038% NaCl), which reduces level of hypertension, attenuates coronary artery disease hence increasing survival
  • 15. Elements of a “promising model”  Tg53 rat model: value and potential  identical genetic background and ability to regulate environmental factors allows well- controlled in vivo studies for cross-talk pathogenesis: a. investigation of mechanisms of coronary plaque development not possible in humans b. methodical in vivo investigation of novel intervention targets c. maximization of genomic-based technologies aimed at the investigation of mechanisms and targets
  • 16. Elements of a “promising model”  Tg53 rat model: value and potential  coronary-specific experimental design for coronary artery-disease studies: with cumulative evidence of vessel-specific genetic factors, the Tg53 coronary-specific phenotype is key  combinatorial modeling: well characterized inbred rat strains allow cross-breeding for interaction studies relevant to human disease  hypertension • diabetes • obesity
  • 17. Elements of a “promising model”  Tg53 rat model: value and potential  as investigative tool: invaluable new insight distinct from that observed in current other models – as a beginning, 1. prelude to culprit plaque: the eccentric macrophage foam-cell rich lesion becomes the “culprit” plaque, thus experimentally “capturing” the beginning of the vulnerable plaque 2. differential pathway hypothesis: proximal vulnerable- culprit coronary lesions develop distinct from more distal stable coronary plaques 3. lesion heterogeneity paradigm: given identical genetic background and environmental factors, lesion heterogeneity at end-stage reflect stochastic endpoints of a common pathogenic framework
  • 18. Elements of a “promising model”  Tg53 rat model: value and potential  as pre-clinical platform • identical genetic background • regulated environmental factors • robust coronary phenotype • instrumentation accessibility • rat physiological and pharmacological information database – allow continuity of comparative analysis for successful new intervention and prevention strategies
  • 19. • ... can’t promise the world – but along with other animal models, can together make a better promise, • but then again, which model can be “promising enough” since even humans – although they are the ultimate benchmarks – make terrible models, if not the worst, for human coronary artery disease ...  Tg53 rat model – “is it promising enough?”
  • 20. Acknowledgment • This work is supported by grants from the National Institutes of Health and American Heart Association.